Fine mapping of anti-ADAMTS13 autoantibodies in acute-phase and remission samples. (A) Flow chart representing an overview of the number of patients and their corresponding plasma or serum samples analyzed in this study. A total of 365 plasma or serum samples from 213 patients were selected and screened for the presence of anti-ADAMTS13 autoantibodies. More than 1 sample was available for 92 patients. Samples were both from acute phase (orange) and remission (blue). Positive samples were further screened for the presence or absence of anti-M, anti-DT, anti-CS, anti-T2-T5, anti-T6-T8, and anti-CUB1-2 autoantibodies. From the positive samples, more than 1 sample was available for 27 patients. These samples can be identified in supplemental Table 1 as samples with the same patient identification number but with a different sample identification number. (B) Comparison of the percentage of samples with detectable anti-M, anti-DT, anti-CS, anti-T2-T5, anti-T6-T8, and anti-CUB1-2 autoantibodies between acute-phase samples (n = 131) and remission samples (n = 50). Fisher’s exact test; *P < .05; ***P < .001; ****P < .0001.